Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 18;7(7):CD001911.
doi: 10.1002/14651858.CD001911.pub4.

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

Sarah J Nevitt  1 , Anthony G Marson, Catrin Tudur Smith
Affiliations

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

Sarah J Nevitt et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an update of a Cochrane Review first published in 2002 and last updated in 2017. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, carbamazepine and phenytoin are commonly-used broad spectrum antiepileptic drugs, suitable for most epileptic seizure types. Carbamazepine is a current first-line treatment for focal onset seizures in the USA and Europe. Phenytoin is no longer considered a first-line treatment, due to concerns over adverse events associated with its use, but the drug is still commonly used in low- to middle-income countries because of its low cost. No consistent differences in efficacy have been found between carbamazepine and phenytoin in individual trials; however, the confidence intervals generated by these trials are wide, and therefore, synthesising the data of the individual trials may show differences in efficacy.

Objectives: To review the time to treatment failure, remission and first seizure with carbamazepine compared with phenytoin when used as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised), or generalised onset tonic-clonic seizures (with or without other generalised seizure types).

Search methods: For the latest update, we searched the following databases on 13 August 2018: the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy's Specialised Register and CENTRAL; MEDLINE; the US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov); and the World Health Organization International Clinical Trials Registry Platform (ICTRP). We handsearched relevant journals and contacted pharmaceutical companies, original trial investigators, and experts in the field.

Selection criteria: Randomised controlled trials comparing monotherapy with either carbamazepine or phenytoin in children or adults with focal onset seizures or generalised onset (tonic-clonic) seizures.

Data collection and analysis: This was an individual participant data (IPD) review. Our primary outcome was time to treatment failure. Our secondary outcomes were time to first seizure post-randomisation, time to six-month remission, time to 12-month remission, and incidence of adverse events. We used Cox proportional hazards regression models to obtain trial-specific estimates of hazard ratios (HRs), with 95% confidence intervals (CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI.

Main results: IPD were available for 595 participants out of 1102 eligible individuals, from four out of 11 trials (i.e. 54% of the potential data). For remission outcomes, a HR greater than 1 indicates an advantage for phenytoin; and for first seizure and withdrawal outcomes, a HR greater than 1 indicates an advantage for carbamazepine. Most participants included in analysis (78%) were classified as experiencing focal onset seizures at baseline and only 22% were classified as experiencing generalised onset seizures; the results of this review are therefore mainly applicable to individuals with focal onset seizures.Results for the primary outcome of the review were: time to treatment failure for any reason related to treatment (pooled HR adjusted for seizure type for 546 participants: 0.94, 95% CI 0.70 to 1.26, moderate-certainty evidence); time to treatment failure due to lack of efficacy (pooled HR adjusted for seizure type for 546 participants: 0.99, 95% CI 0.69 to 1.41, moderate-certainty evidence); both showing no clear difference between the drugs and time to treatment failure due to adverse events (pooled HR adjusted for seizure type for 546 participants: 1.27, 95% CI 0.87 to 1.86, moderate-certainty evidence), showing that treatment failure due to adverse events may occur earlier on carbamazepine than phenytoin, but we cannot rule out a slight advantage to carbamazepine or no difference between the drugs.For our secondary outcomes (pooled HRs adjusted for seizure type), we did not find any clear differences between carbamazepine and phenytoin: time to first seizure post-randomisation (582 participants): 1.15, 95% CI 0.94 to 1.40, moderate-certainty evidence); time to 12-month remission (551 participants): 1.00, 95% CI 0.79 to 1.26, moderate-certainty evidence); and time to six-month remission (551 participants): 0.90, 95% CI 0.73 to 1.12, moderate-certainty evidence).For all outcomes, results for individuals with focal onset seizures were similar to overall results (moderate-certainty evidence), and results for the small subgroup of individuals with generalised onset seizures were imprecise, so we cannot rule out an advantage to either drug, or no difference between drugs (low-certainty evidence). There was also evidence that misclassification of seizure type may have confounded the results of this review, particularly for the outcome 'time to treatment failure'. Heterogeneity was present in analysis of 'time to first seizure' for individuals with generalised onset seizures, which could not be explained by subgroup analysis or sensitivity analyses.Limited information was available about adverse events in the trials and we could not compare the rates of adverse events between carbamazepine and phenytoin. Some adverse events reported on both drugs were abdominal pain, nausea, and vomiting, drowsiness, motor and cognitive disturbances, dysmorphic side effects (such as rash).

Authors' conclusions: Moderate-certainty evidence provided by this systematic review does not show any differences between carbamazepine and phenytoin in terms of effectiveness (retention) or efficacy (seizure recurrence and seizure remission) for individuals with focal onset or generalised onset seizures.However, some of the trials contributing to the analyses had methodological inadequacies and inconsistencies, which may have had an impact on the results of this review. We therefore do not suggest that results of this review alone should form the basis of a treatment choice for a person with newly-onset seizures. We did not find any evidence to support or refute current treatment policies. We implore that future trials be designed to the highest quality possible, with consideration of masking, choice of population, classification of seizure type, duration of follow-up, choice of outcomes and analysis, and presentation of results.

PubMed Disclaimer

Conflict of interest statement

SJN: none known AGM: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC). CTS: none known

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Time to treatment failure ‐ any reason related to the treatment (CBZ: carbamazepine; PHT: phenytoin)
5
5
Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (CBZ: carbamazepine; PHT: phenytoin)
6
6
Time to treatment failure due to adverse events (CBZ: carbamazepine; PHT: phenytoin)
7
7
Time to treatment failure due to adverse events, by epilepsy type (CBZ: carbamazepine; PHT: phenytoin)
8
8
Time to treatment failure due to lack of efficacy (CBZ: carbamazepine; PHT: phenytoin)
9
9
Time to treatment failure due to lack of efficacy, by epilepsy type (CBZ: carbamazepine; PHT: phenytoin)
10
10
Time to first seizure (CBZ: carbamazepine; PHT: phenytoin)
11
11
Time to first seizure, by epilepsy type (CBZ: carbamazepine; PHT: phenytoin)
12
12
Time to 12 month remission (CBZ: carbamazepine; PHT: phenytoin)
13
13
Time to 12 month remission, by epilepsy type (CBZ: carbamazepine; PHT: phenytoin)
14
14
Time to 6 month remission (CBZ: carbamazepine; PHT: phenytoin)
15
15
Time to 6 month remission, by epilepsy type (CBZ: carbamazepine; PHT: phenytoin)
16
16
Cumulative incidence plots, proportional hazards assumption checks
1.1
1.1. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 1 Time to treatment failure (any reason related to the treatment).
1.2
1.2. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 2 Time to treatment failure due to adverse events.
1.3
1.3. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 3 Time to treatment failure due to lack of efficacy.
1.4
1.4. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 4 Time to treatment failure (any reason related to the treatment) ‐ by epilepsy type.
1.5
1.5. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 5 Time to treatment failure due to adverse events ‐ by epilepsy type.
1.6
1.6. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 6 Time to treatment failure due to lack of efficacy ‐ by epilepsy type.
1.7
1.7. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 7 Time to first seizure post‐randomisation.
1.8
1.8. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 8 Time to first seizure post‐randomisation ‐ by epilepsy type.
1.9
1.9. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 9 Time to achieve 12‐month remission.
1.10
1.10. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 10 Time to achieve 12‐month remission ‐ by epilepsy type.
1.11
1.11. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 11 Time to achieve six‐month remission.
1.12
1.12. Analysis
Comparison 1 Carbamazepine (CBZ) versus phenytoin (PHT) monotherapy, Outcome 12 Time to achieve six‐month remission ‐ by epilepsy type.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Callaghan 1985 {published data only}
    1. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A comparative study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. British Journal of Clinical Practice 1983;27:7‐9. - PMC - PubMed
    1. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 1985;48(7):639‐44. - PMC - PubMed
    1. Goggin T, Casey C, Callaghan N. Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy. Irish Medical Journal 1986;79(6):150‐6. - PubMed
Czapinski 1997 {published data only}
    1. Czapinski P, Terczynski A, Czapinska E. Randomised 36‐month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with focal complex seizures. Epilepsia 1997;38 Suppl(3):42.
De Silva 1996 {published and unpublished data}
    1. Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347(9003):709‐13. - PubMed
Forsythe 1991 {published data only}
    1. Berg I, Butler A, Ellis M, Foster J. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Developmental Medicine and Child Neurology 1993;35(2):149‐57. - PubMed
    1. Forsythe I, Butler R, Berg I, McGuire R. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology 1991;33(6):524‐34. - PubMed
Heller 1995 {published and unpublished data}
    1. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry 1995;58(1):44‐50. - PMC - PubMed
Mattson 1985 {published and unpublished data}
    1. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado‐Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in focal and secondary generalized tonic‐clonic seizures. New England Journal of Medicine 1985;313(3):145‐51. - PubMed
Miura 1993 {published data only}
    1. Miura H. Developmental and therapeutic pharmacology of antiepileptic drugs. Japanese Journal of Psychiatry and Neurology 1993;47(2):169‐74. - PubMed
Ogunrin 2005 {published and unpublished data}
    1. Ogunrin O, Adamolekun B, Ogunniyi A. Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences 2005;24:18‐24.
Pulliainen 1994 {published data only}
    1. Pulliainen V, Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long‐term monotherapy: a two‐year follow‐up. Epilepsia 1995;36(12):1195‐202. - PubMed
    1. Pulliainen V, Jokelainen M. Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients. Acta Neurologica Scandinavica 1994;89(2):81‐6. - PubMed
Ramsay 1983 {published data only}
    1. Berger JR, Ramsay RE, Wilder BJ, Bruni J. A double‐blind study comparing carbamazepine to phenytoin as initial seizure therapy. Neurology 1981;31(4 Pt 2):159. - PubMed
    1. Ramsay RE, Wilder BJ, Berger JR, Bruni J. A double blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983;33(7):904‐10. - PubMed
Ravi Sudhir 1995 {published data only}
    1. Ravi Sudhir RV, Sawhney IM, Prabhakar S, Pershad D, Nain CK. Comparative cognitive effects of phenytoin and carbamazepine in adult epileptics. Neurology India 1995;43(4):186‐92. - PubMed

References to studies excluded from this review

Bird 1966 {published data only}
    1. Bird CA, Griffin BP, Miklaszewska JM, Galbraith AW. Tegretol (carbamazepine): a controlled trial of new anti‐convulsant. British Journal of Psychiatry 1966;112:737‐42.
Bittencourt 1993 {published data only}
    1. Bittencourt PR, Antoniuk SA, Bigarella MM, Costa JC, Doro MP, Ferreira AS, et al. Carbamazepine and phenytoin in epilepsies refractory to barbiturates: efficacy, toxicity and mental function. Epilepsy Research 1993;16(2):147‐55. - PubMed
Canadian Study 1998 {published data only}
    1. Bawden HN, Camfield CS, Camfield PR, Cunningham C, Darwish H, Dooley JM, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Research 1999;33(2‐3):133‐43. - PubMed
    1. Canadian Study Group for Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 1998;39(9):952‐9. - PubMed
Cereghino 1974 {published data only}
    1. Cereghino JJ, Brock JJ, Meter JC, Penry JK, Smith LD, White BG. Carbamazepine for epilepsy. A controlled prospective evaluation. Neurology 1974;24(5):401‐10. - PubMed
    1. Cereghino JJ, Brock JT, White BG, Penry JK. Evaluation of carbamazepine in epileptic patients. Neurology 1973;23(4):433. - PubMed
Hakami 2012 {published data only}
    1. Hakami T, Todaro M, Petrovski S, MacGregor L, Velakoulis D, Tan M, et al. Substitution monotherapy with levetiracetam vs older antiepileptic drugs: A randomized comparative trial. Archives of Neurology 2012;69(12):1563‐71. - PubMed
Kaminow 2003 {published data only}
    1. Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy and Behaviour 2003;4(6):659‐66. - PubMed
    1. Martinez W, Kaminow L, Nanry KP, Hammer AE, Barrett PS. Evaluation of lamotrigine versus carbamazepine, phenytoin, or divalproex sodium as monotherapy for epilepsy patients who failed or could not tolerate previous antiepileptic drug therapy. Epilepsia 2000;41(Suppl 7):100.
Kosteljanetz 1979 {published data only}
    1. Kosteljanetz M, Christiansen J, Dam AM, Hansen BS, Pedersen H, Dam M. Carabamazepine vs phenytoin. A controlled clinical trial in focal motor and generalized epilepsy. Archives of Neurology 1979;36(1):22‐4. - PubMed
Kuzuya 1993 {published data only}
    1. Kuzuya T, Hasegawa T, Shimizu K, Nabeshima T. Effect of anti‐epileptic drugs on serum zinc and copper concentrations in epileptic patients. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1993;31(2):61‐5. - PubMed
Rajotte 1967 {published data only}
    1. Rajotte P, Jilek W, Jilek L, Perales A, Giard N, Bordeleau J, et al. The anti‐epileptic and psychotropic properties of carbamazepine (Tegretol) [Proprietes antiepileptiques et psychotropes de la carbamazepine (Tegretol)]. L'Union Medicale du Canada 1967;96(10):1200‐6. - PubMed
Rysz 1994 {published data only}
    1. Rysz A. Effect of monotherapy with phenytoin or carbamazepine on somatosensory evoked potentials in patients with newly diagnosed epilepsy. Polski Tygodnik Lekarski 1994;49(4‐5):79‐81. - PubMed
Sabers 1995 {published data only}
    1. Sabers A, Moller A, Dam M, Smed A, Arlien‐Soborg P, Buchman J, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurologica Scandinavica 1995;92(1):19‐27. - PubMed
Shakir 1980 {published data only}
    1. Shakir RA. Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants. The place of sodium valproate in the treatment of epilepsy. Royal Society of Medicine International Congress and Symposium No. 30. London: Academic Press Inc (London) Ltd and the Royal Society of Medicine, 1980:7‐16.
Shorvon 1978 {published data only}
    1. Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH. One drug for epilepsy. British Medical Journal 1978;1(6111):474‐6. - PMC - PubMed
Simonsen 1976 {published data only}
    1. Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelboe J. A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy. Epilepsia 1976;17(2):169‐76. - PubMed
    1. Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelboe J. A double blind study of carbamazepine and diphenylhydantoin in temporal lobe epilepsy. Acta Neurologica Scandinavica Supplementum 1975;60:39‐42. - PubMed
Troupin 1975 {published data only}
    1. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double‐blind comparison with phenytoin. Neurology 1977;27(11):1023‐8. - PubMed
    1. Troupin A, Ojemann LM, Halpern L, Dodrill C, Wilkus R, Friel P, et al. Carbamazepine: a double blind comparison with phenytoin. Neurology 1977;27(6):511‐9. - PubMed
    1. Troupin AS, Green JR, Halpern LM. Carbamazepine (Tegretol) as an anticonvulsant. A controlled double‐blind comparison with diphenylhydantoin (Dilantin). Acta Neurologica Scandinavica Supplement 1975;60:13‐26. - PubMed
    1. Wilkus RJ, Dodrill CB, Troupin AS. Carbamazepine and the electroencephalogram of epileptics: a double blind study in comparison to phenytoin. Epilepsia 1978;19(3):283‐91. - PubMed
Zeng 2010 {published data only}
    1. Zeng K, Wang X, Xi Z, Yan Y. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clinical Neurology and Neurosurgery 2010;112(4):291‐5. - PubMed

Additional references

Annegers 1999
    1. Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40(4):502‐6. - PubMed
Bromley 2014
    1. Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD010236.pub2] - DOI - PMC - PubMed
Carl 1992
    1. Carl GF, Smith ML. Phenytoin‐folate interactions: differing effects of the sodium salt and the free acid of phenytoin. Epilepsia 1992;33(2):372‐5. - PubMed
Cockerell 1995
    1. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140‐4. - PubMed
Commission 1981
    1. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22(4):489‐501. - PubMed
Commission 1989
    1. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389‐99. - PubMed
Gladstone 1992
    1. Gladstone DJ, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology 1992;6(3):257‐61. - PubMed
Granger 1995
    1. Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, et al. Modulation of the gamma aminobutyricacid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology 1995;47(6):1189‐96. - PubMed
Gruber 1962
    1. Gruber CM, Brock JT, Dyken MD. Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, dipheylhydantoin, ethotoin, metharbital, and methylphenylhydantion in motor seizures. Clinical Pharmacology and Therapeutics 1962;3:23‐8. - PubMed
Hauser 1993
    1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935‐1984. Epilepsia 1993;34(3):453‐68. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. Cochrane.
Hirtz 2007
    1. Hirtz D, Thurman DJ, Gwinn‐Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders?. Neurology 2007;68(5):326‐37. - PubMed
ILAE 1998
    1. ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39(7):799‐803. - PubMed
ILAE 2006
    1. Glauser T, Ben‐Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: Evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094‐120. - PubMed
Jones 1996
    1. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313(7048):36‐9. - PMC - PubMed
Juul‐Jenson 1983
    1. Juul‐Jenson P, Foldspang A. Natural history of epileptic seizures. Epilepsia 1983;24(3):297‐312. - PubMed
Kirkham 2010
    1. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. - PubMed
Kwan 2000
    1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine 2000;342(5):314‐9. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Liporace 1994
    1. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994;35(5):1026‐8. - PubMed
MacDonald 2000
    1. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology 2000;48(6):833‐41. - PubMed
Malafosse 1994
    1. Malfosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R. Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic. Eastleigh: John Libbey and Company, 1994.
Marson 2000
    1. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD001030] - DOI - PMC - PubMed
Matlow 2012
    1. Matlow J, Koren G. Is carbamazepine safe to take during pregnancy?. Candian Family Physician 2012;58(2):163‐4. - PMC - PubMed
Meador 2008
    1. Meador K, Reynolds M, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: A systematic review and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research 2008;81(1):1‐13. - PMC - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. BMJ 2009;339:b2535. - PMC - PubMed
Morrow 2006
    1. Morrow J, Russel A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry 2006;77(2):193‐8. - PMC - PubMed
Murray 1994
    1. Murray CJ, Lopez AD. Global Comparative Assessments in the Health Sector. Geneva: World Health Organization, 1994.
Nevitt 2017a
    1. Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews 2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] - DOI - PMC - PubMed
Nevitt 2018a
    1. Nevitt SJ, Tudur Smith C, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 6. [DOI: 10.1002/14651858.CD001031.pub4] - DOI - PMC - PubMed
Nevitt 2018b
    1. Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 8. [DOI: 10.1002/14651858.CD001769.pub4] - DOI - PMC - PubMed
Nevitt 2018c
    1. Nevitt SJ, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 10. [DOI: 10.1002/14651858.CD003615.pub4] - DOI - PMC - PubMed
Nevitt 2018d
    1. Nevitt SJ, Marson AG, Tudur‐Smith C. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 10. [DOI: 10.1002/14651858.CD001904.pub4] - DOI - PMC - PubMed
Nevitt 2019
    1. Nevitt SJ, Sudell M, Tudur Smith C, Marson A. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2019, Issue 6. [DOI: 10.1002/14651858.CD012065.pub3] - DOI - PMC - PubMed
Ngugi 2010
    1. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life‐time epilepsy: a meta‐analytic approach. Epilepsia 2010;51(5):883‐90. - PMC - PubMed
NICE 2012
    1. National Institute for Health and Care Excellence. Epilepsies: diagnosis and management. www.nice.org.uk/guidance/cg137 2012 (accessed 12 May 2019).
Nolan 2013a
    1. Nolan SJ, Sutton L, Marson A, Tudur Smith C. Consistency of outcome and statistical reporting of time‐to‐event data: the impact on Cochrane Reviews and meta‐analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health. Quebec City, 2013:114‐5.
Nolan 2013b
    1. Nolan SJ, Tudur Smith C, Pulman J, Marson AG. Phenobarbitone versus phenytoin monotherapy for focal onset seizures and generalised onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD002217.pub2] - DOI - PubMed
Nulman 1997
    1. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics 1997;68(1):18‐24. - PubMed
Olaffsson 2005
    1. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorfer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology 2005;4(10):627‐34. - PubMed
Pal 1998
    1. Pal DK, Das T, Chaudhury G, Johnson AL, Neville BG. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351(9095):19‐23. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analysis of the published literature for survival end‐points. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Ragsdale 1991
    1. Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage dependent inhibition of type hA Naı channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Molecular Pharmacology 1991;40:756‐65. - PubMed
Sander 1996
    1. Sander JW, Shorvon SD. Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61(5):433‐43. - PMC - PubMed
Sander 2004
    1. Sander JW. The use of anti‐epileptic drugs ‐ Principles and practice. Epilepsia 2004;45(6):28‐34. - PubMed
Scheffer 2017
    1. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512‐21. - PMC - PubMed
Scheinfeld 2003
    1. Scheinfeld N. Phenytoin in cutaneous medicine: Its uses, mechanisms and side effects. Dermatology Online Journal 2003;9(3):6. - PubMed
Shields 1983
    1. Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33(11):1487‐9. - PubMed
Snead 1985
    1. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine 1985;313(15):916‐21. - PubMed
Stata 2015 [Computer program]
    1. StataCorp. Stata Statistical Software: Release 14. CollegeStation, TX: StataCorp LP, 2015.
Tennis 1997
    1. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49(2):542‐6. - PubMed
Tudur Smith 2007
    1. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007;5(8):34. - PMC - PubMed
Wallace 1997
    1. Wallace H, Shorvon SD, Hopkins A, O’Donoghue M. National Society of Epilepsy Guidelines. London: Royal College of Physicians, 1997.
Weston 2016
    1. Weston J, Bromley R, Jackson CF, Adab N, Clayton‐Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews 2016, Issue 11. [DOI: 10.1002/14651858.CD010224.pub2] - DOI - PMC - PubMed
Wilder 1995
    1. Wilder BJ. Phenytoin: clinical use. Antiepileptic Drugs. 4th Edition. New York: Raven Press, 1995:339‐44.
Williamson 2000
    1. Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick DW. Individual patient data meta‐analysis of randomized antiepileptic drug monotherapy trials. Journal of Evaluation in Clinical Practice 2000;6(2):205‐14. - PubMed
Williamson 2002
    1. Williamson PR, Tudur Smith C, Hutton JL, Marson AG. Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine 2002;21(11):3357‐51. - PubMed
Willow 1985
    1. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage sensitive sodium channels in neuroblastoma cells. Molecular Pharmacology 1985;27(5):549‐58. - PubMed

References to other published versions of this review

Nevitt 2017b
    1. Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] - DOI - PMC - PubMed
Nolan 2015
    1. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD001911.pub2] - DOI - PubMed
Tudur Smith 2002
    1. Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD001911] - DOI - PubMed
Tudur Smith 2010
    1. Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD001911] - DOI - PubMed
Wilson 2000
    1. Wilson HE, Marson AG, Williamson PR, Lopes‐Lima JM, Hutton JL, Chadwick DW. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD001911] - DOI - PMC - PubMed

Publication types